Close search box Search


Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) signed a drug development agreement with Oxford StemTech, the custom cell reprogramming specialist.

The contract research group will provide support for OCT’s drug development efforts, starting with programmes three and four, targeting pain, neurology and inflammation.

Using cell technology pioneered by Professor Zameel Cader and his team, the aim is to predict in the lab human responses to OCT’s cannabinoid-based treatments using re-engineered stem cells.

Read the full news story here.

Date posted: 17 November 2021
Article tag: Oxford Cannabinoid Technologies

Related articles

View all news